Melanotan 2: what the research shows (and the risks)

Melanotan 2 (often written MT-II or MT-2) is a lab-made peptide that switches on the body's tanning machinery, so the skin darkens with little or no sun. It is sold online as a "tanning injection," but no health agency anywhere has approved it for that use, and the published evidence is thin, old, and heavily weighted toward harm. This review walks through how the peptide works, what the studies and case reports actually found, how it compares to the one approved drug in its family, and the safety problems that keep showing up in the medical literature.

What Melanotan 2 is

Melanotan 2 is a synthetic copy of part of a natural hormone your body already makes: alpha-melanocyte-stimulating hormone (α-MSH). Researchers at the University of Arizona built it in the early 1990s while looking for a "sunless tanning" drug that might protect fair-skinned people from sun damage. The original idea was reasonable. A darker tan means more melanin, and more melanin blocks some ultraviolet (UV) light. If you could trigger a tan without UV exposure, the thinking went, you might lower skin-cancer risk.

That is where the clean story ends. The compound that became an approved medicine is a close cousin called afamelanotide (brand name Scenesse), not Melanotan 2. Melanotan 2 itself was never carried through full human trials by a drug company. It leaked into the gray market instead, where it is now sold as a powder for self-injection, a nasal spray, or a so-called "tanning jab." None of those products are quality-controlled, dose-standardized, or legal to sell for human use in the United States, the United Kingdom, Australia, or the European Union.

A quick note on names, because they get mixed up constantly:

Name	What it is	Approval status
Melanotan 1 / afamelanotide (Scenesse)	A more selective α-MSH analog; one MC1R-focused agonist	FDA-approved in 2019 for a rare disease (see below)
Melanotan 2 (MT-II)	A shorter, non-selective α-MSH analog	Not approved anywhere for human use
"Melanotan nasal spray / tanning jabs"	Gray-market MT-II products	Illegal to sell for human use; unregulated

How it works in the body

To understand both the appeal and the danger of Melanotan 2, you need to know one fact: it is a non-selective agonist. That means it does not stick to just one target. It binds and switches on several different melanocortin receptors at once, and each of those receptors controls something different.

The main receptors are:

MC1R — sits on pigment cells (melanocytes). Switching it on drives production of eumelanin, the dark-brown pigment responsible for a tan. This is the effect users want.
MC3R and MC4R — sit in the brain and regulate appetite, body weight, and sexual arousal. Activating these is why MT-II can suppress hunger and cause spontaneous erections.
MC5R — involved in the function of glands like sweat and oil glands.

Afamelanotide, the approved drug, was designed to act more on the pigment side. Melanotan 2 hits everything. That lack of selectivity is the root of most of its side effects: the same molecule that darkens skin also messes with appetite centers, blood pressure control, and the erection reflex. You cannot dial in the tan without also dialing in the rest.

The tanning effect itself is real and biologically straightforward. By pushing melanocytes to make more eumelanin, the skin gets darker over days to weeks. Because the pigment is being made by your own cells, the color tends to look more like a genuine tan than a spray-on bronzer. But "it works" and "it's safe" are two completely different questions, and the evidence splits sharply on that line.

It also helps to understand the difference between the two main kinds of melanin. Eumelanin is the brown-black pigment that actually absorbs UV and offers some protection. Pheomelanin is the reddish-yellow pigment more common in fair, freckled skin, and it does little to shield against UV — in fact it can generate damaging free radicals under sunlight. Melanotan 2 pushes melanocytes toward eumelanin, which is the "protective" type, and that is the kernel of truth behind the original sun-protection hypothesis. The problem is that triggering this shift with an untested, non-selective injectable drug is a very different proposition from the careful, single-target approach a real medicine would take. The mechanism being plausible is not the same as the product being safe. People often hear "it makes the protective kind of melanin" and assume that settles the safety question. It does not. The pathway is sound; the delivery vehicle — gray-market powder of unknown purity, self-injected at a guessed dose — is the problem.

What the actual evidence shows

Here is the honest summary: the efficacy evidence for tanning is mostly anecdotal and short-term, and the safety evidence is dominated by case reports — single-patient stories of things going wrong. There is no large, modern, randomized controlled trial of Melanotan 2 for cosmetic tanning. None. The strongest published body of work is a 2017 review in the International Journal of Dermatology that pulled together the scattered case reports and small studies on unregulated α-MSH analog use, and its overall conclusion was a warning, not an endorsement.

When researchers and clinicians have looked at MT-II, they keep finding the same cluster of problems. The table below grades the main claims by how strong the supporting evidence is.

Claim about Melanotan 2	What the evidence is	Strength of evidence
It darkens skin / produces a tan	Case series, user surveys, mechanism is well understood	Moderate — effect is real but not from rigorous trials
It suppresses appetite	Mechanism (MC4R) plus user reports	Weak to moderate; not the approved or tested use
It causes nausea and flushing	Reported in nearly every case series and survey	Strong — among the most consistent findings
It darkens and changes existing moles	Multiple case reports and reviews	Moderate to strong; biologically plausible
It is linked to melanoma	A handful of case reports; causation not proven	Weak — association only, major confounders
It causes priapism (prolonged erection)	Multiple published case reports and overdoses	Strong as a known adverse effect
It causes rhabdomyolysis / systemic toxicity	At least one detailed published case	Documented but rare
It is safe long-term	No data exists beyond short follow-up	None — absence of evidence, not evidence of safety

A few things deserve emphasis. First, much of the positive buzz about Melanotan 2 comes from vendor websites and forums, not from peer-reviewed science. Those sources have a financial interest in selling the product, and they often cite precise-sounding statistics ("47 documented cases," "blood pressure rises in 40 to 60 percent of users") that trace back to no verifiable primary study. Treat any oddly specific number from a peptide-selling site as marketing until you can find the original paper. We have deliberately not repeated those figures here, because we could not verify them.

Second, the case-report nature of the safety literature cuts both ways. Case reports prove that bad outcomes can happen, but they cannot tell you how often they happen, because nobody is tracking the denominator — the total number of people using the drug. So the true rate of any single harm is unknown. That uncertainty is itself a reason for caution in a product taken for purely cosmetic reasons.

Third, it is worth being clear about what a strong evidence base would even look like, because Melanotan 2 has none of it. For a drug you inject for years, you would want randomized controlled trials with hundreds of participants, a placebo group, blinded outcome assessment, and follow-up measured in years, not weeks. You would want pharmacokinetic data showing how the drug is absorbed and cleared, dose-response curves, and post-marketing surveillance tracking rare harms across thousands of users. Afamelanotide, the approved cousin, has most of that. Melanotan 2 has scattered case reports, a few user surveys, and a mechanism that makes sense on paper. When sellers describe it as "well-researched," that is the gap they are papering over. A plausible mechanism plus enthusiastic forum testimony is not the same as proof, and it is nowhere near the bar a medicine has to clear.

If you want a broader view of how peptide evidence is graded across the field, our complete guide to peptide therapy lays out the same skeptical framework applied to other compounds, and our breakdown of common peptide myths shows how often confident-sounding claims fall apart under scrutiny.

Melanotan 2 vs. afamelanotide (the approved cousin)

The cleanest way to see what "approved and tested" looks like is to compare Melanotan 2 to afamelanotide. They are chemically related, both work on the melanocortin system, and both darken skin. One went through the full regulatory process. The other did not.

Afamelanotide (Scenesse) was approved by the U.S. Food and Drug Administration in 2019. Its approved use is narrow and specific: increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare inherited disorder in which sunlight causes severe pain. It is delivered as a controlled 16 mg implant placed under the skin by a healthcare provider roughly every two months. It is not approved, marketed, or legal as a cosmetic tanning product.

Feature	Afamelanotide (Scenesse)	Melanotan 2 (gray market)
Approval	FDA-approved (2019)	None, anywhere, for human use
Approved use	Rare disease (EPP), not tanning	Sold illegally as cosmetic tanning
Receptor targeting	More MC1R-focused	Non-selective (MC1R, MC3R, MC4R, MC5R)
Delivery	Provider-placed implant, fixed dose	Self-injection or nasal spray, unknown dose
Quality control	Pharmaceutical-grade	Unregulated; purity and dose vary widely
Medical supervision	Required	None

The contrast matters. The approval of afamelanotide is sometimes used by sellers to imply that "melanotan is FDA-approved." It is not. A different, more selective molecule, used for a rare medical condition under a doctor's care, was approved. That tells you the melanocortin pathway can be drugged safely enough for a specific patient group. It tells you nothing about the safety of injecting an unregulated, non-selective version for a beach tan.

Safety: the part that should stop you

The reported harms of Melanotan 2 fall into a few buckets. Some are merely unpleasant. Others are serious.

Common, lower-severity effects

Nausea, facial flushing, and yawning show up in almost every published account. Many users also report fatigue and a loss of appetite (the appetite suppression is a direct MC4R effect, not a coincidence). These usually appear soon after a dose and fade.

Skin and mole changes

This is the one that worries dermatologists most. Melanotan 2 stimulates pigment cells throughout the body, not just where you want a tan. Reports describe existing moles getting darker and larger, and new moles appearing. Because the drug is acting on the exact cells that can turn cancerous, any change in a mole becomes harder to interpret — a darkening mole could be a harmless drug effect or an early warning of melanoma, and you cannot tell by looking.

The melanoma question

Several case reports describe people developing melanoma during or shortly after Melanotan 2 use, including reports published in the British Journal of Dermatology and the Australasian Journal of Dermatology. Here is the honest read: these reports raise a serious flag, but they do not prove the drug causes melanoma. The reason is confounding. People who inject a tanning drug are also, very often, heavy users of tanning beds and sun exposure — both well-established melanoma risk factors on their own. So you cannot cleanly separate the drug's effect from the company it keeps. The biologically plausible concern (stimulating pigment cells while also chasing UV) plus the cluster of case reports is enough to justify real caution, even without proof of causation.

Priapism and sexual effects

Because Melanotan 2 hits MC4R, it can trigger spontaneous, sometimes prolonged erections. This is well documented — including published cases of priapism (a painful erection lasting hours) severe enough to require emergency treatment, some tied to overdose. Priapism is a medical emergency; left untreated it can cause permanent damage.

Systemic toxicity

At least one detailed published case describes a young man who developed systemic toxicity and rhabdomyolysis (muscle breakdown that can damage the kidneys) after injecting Melanotan 2. Rhabdomyolysis is rare but dangerous. Other reports describe nausea severe enough to need hospital care.

Blood pressure and the heart

Reports also describe cardiovascular effects, including changes in blood pressure and heart rate. The melanocortin system has real connections to cardiovascular control, so this is biologically plausible rather than surprising. The catch, again, is that the precise frequency is unknown. You will see specific percentages quoted on vendor pages — figures like "40 to 60 percent of users" — but we could not trace those numbers to any verifiable primary study, so we are not repeating them as fact. What is fair to say is that cardiovascular effects are reported, the mechanism supports them, and anyone with existing heart or blood-pressure problems is taking an unquantified risk.

The injection problem

Most of the safety discussion above assumes a clean, correctly dosed product. With gray-market Melanotan 2, you cannot assume that. The powder is reconstituted by the user, the concentration is guessed, and the purity is unverified. Independent testing of gray-market peptides routinely turns up products that are underdosed, overdosed, contaminated, or not even the labeled compound. Sharing or reusing needles adds infection risk on top of that. If you are going to handle injectable peptides at all, our peptide reconstitution guide covers the basics of doing it cleanly — but doing it cleanly does not make an unapproved drug safe. Clean technique on a contaminated, mislabeled vial still injects a contaminated, mislabeled vial.

The regulatory and legal picture

Regulators have been consistent and blunt. The FDA has formally treated Melanotan 2 as an unapproved new drug. In one enforcement action, the agency described a company's Melanotan 2 product directly as "an unapproved new drug" marketed illegally as an injectable tanning product. Selling it for human use in the U.S. is illegal. The same is true across the U.K., Europe, and Australia, where health agencies have issued repeated public warnings about "tanning jabs."

What gets sold instead is labeled "for research use only" or "not for human consumption." That label is a legal dodge, not a safety statement. It lets vendors ship the product while disclaiming responsibility for what buyers do with it. If you want a fuller map of what is and is not legal in the peptide space, see our peptide legality guide, which covers how the "research use only" loophole works in practice.

Who is it for?

Honest answer: from an evidence-based standpoint, almost no one outside a supervised medical context.

People wanting a cosmetic tan — this is the main reason people use Melanotan 2, and it is the use with the worst risk-to-benefit math. You are taking an unapproved, non-selective drug with documented serious harms, for a purely cosmetic result that sunless tanning lotions (DHA-based self-tanners) can approximate with no systemic risk at all.
People with EPP or other photosensitivity disorders — the melanocortin pathway can genuinely help here, but the right tool is the FDA-approved, supervised implant (afamelanotide), prescribed by a specialist, not gray-market MT-II.
People with many moles, a family history of melanoma, or fair skin that burns easily — this is the group with the most to lose. Stimulating pigment cells and masking mole changes in someone already at melanoma risk is the worst-case scenario.

If your underlying goal is something Melanotan 2 is rumored to help with — appetite control, for example — there are far better-studied options. Our roundup of alternatives that actually have evidence behind them is a more sensible starting point than an illegal tanning injection.

The bottom line

Melanotan 2 does what it claims in one narrow sense: it darkens skin by switching on your own pigment cells. But it does so as an unapproved, unregulated, non-selective drug, and the medical literature on it is dominated by reports of harm — nausea, darkening and changing moles, priapism, systemic toxicity, and a real (if unproven) melanoma concern. There is no quality long-term safety data, no modern controlled trial for tanning, and no legal pathway to buy it for human use. The one approved member of its drug family, afamelanotide, exists precisely because it went through the testing Melanotan 2 never did, and it is reserved for a rare disease under medical supervision. For a cosmetic tan, the risk-to-benefit math does not come close to working.

Frequently Asked Questions

Is Melanotan 2 FDA-approved?

No. Melanotan 2 is not approved by the FDA — or any major regulator — for any use in humans. A different, more selective molecule called afamelanotide (Scenesse) was FDA-approved in 2019, but only for a rare inherited disorder called erythropoietic protoporphyria, and only as a provider-placed implant. Sellers sometimes blur these two compounds to imply approval; the approval does not apply to Melanotan 2 or to tanning.

Does Melanotan 2 cause cancer?

The honest answer is "unproven but concerning." Several published case reports describe melanoma developing in Melanotan 2 users, but these reports cannot prove cause and effect, partly because many users also use tanning beds — an independent, well-established melanoma risk. The bigger practical problem is that the drug darkens and changes existing moles, which can hide or mimic the early signs of skin cancer.

Why does Melanotan 2 cause erections and nausea?

Because it is a non-selective drug. It switches on several melanocortin receptors at once, not just the one that controls tanning. The MC4R receptor it activates is involved in sexual arousal and appetite, which is why prolonged erections (priapism) and nausea are among the most consistently reported effects.

How is Melanotan 2 different from afamelanotide (Scenesse)?

Afamelanotide is more focused on the pigment receptor (MC1R), was tested in clinical trials, is pharmaceutical-grade, and is delivered as a fixed-dose implant under medical supervision for a specific disease. Melanotan 2 is non-selective, untested in large trials, sold as an unregulated powder or nasal spray for self-injection, and illegal to sell for human use.

Are gray-market "tanning jabs" the same as research-grade peptide?

No, and even "research-grade" does not mean safe to inject. Products sold as Melanotan 2 are unregulated, with unverified purity and dose, often labeled "for research use only" as a legal workaround. That label disclaims responsibility; it does not make the product clean, correctly dosed, or safe to put in your body.

Medical disclaimer: This article is for general information only and is not medical advice. Melanotan 2 is not approved for human use. Talk to a licensed physician before using any peptide or making decisions about your health.